[18F]-FDG positron imaging in clinical management of lymphoma patients
- 7 May 2001
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 38 (3) , 193-221
- https://doi.org/10.1016/s1040-8428(01)00127-5
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging The Visual Response Score and the Change in Total Lesion GlycolysisClinical Positron Imaging, 1999
- Whole-body 18F-FDG PET for the evaluation of patients with Hodgkinʼs disease and non-Hodgkinʼs lymphomaNuclear Medicine Communications, 1999
- Positron Emission Tomography with 18-Fluorodeoxyglucose in the Staging and Follow-up of Lymphoma in the ChestActa Oncologica, 1999
- Extranodal malignant lymphoma: detection with FDG PET versus CT.Radiology, 1998
- Positron Emission Tomography in Diagnosis and Therapy Monitoring of Patients with LymphomaClinical Positron Imaging, 1998
- Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.Radiology, 1997
- Differential Diagnosis of CNS Lesions in AIDS Patients by FDG-PETJournal of Computer Assisted Tomography, 1995
- Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomasEuropean Journal of Nuclear Medicine and Molecular Imaging, 1995
- FDG-PET for predicting the prognosis of malignant lymphomaAnnals of Nuclear Medicine, 1994
- Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT.Radiology, 1994